Sepracor‘s experimental epilepsy drug (Stedesa) proceeds to FDA review. STEDESA, a new chemical entity, is a novel voltage-gated sodium channel blocker. STEDESA has been studied in three Phase III, multi-center, randomized, placebo-controlled trials, which involved more than 1,000 patients from 23 countries. Patients involved in the trials had a history of at least four partial-onset seizures per month despite treatment with one to three concomitant antiepileptic drugs…more
Glaxo makes a deal for deuterium drug technology – Patrick Vallance, Glaxo’s head of drug discovery, said Concert’s approach to deuterium modification of medicines had broad potential to enhance certain drug properties. Deuterium is a heavy isotope of hydrogen and therefore forms a stronger chemical bond to a carbon atom of a molecule. Researchers believe this may substantially improve the metabolic properties of medicines, making them more effective…more Also, GSK announced encouraging results for a new (experimental) oncology drug for kidney cancer: Today, GlaxoSmithKline announced the results of a Phase III study demonstrating that pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo…more
Pfizer halts Sutent trial in advanced breast cancer – Pfizer Inc today announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer. The independent Data Monitoring Committee (DMC) found that treatment with sunitinib in combination with paclitaxel would be unable to meet the primary endpoint of superior progression-free survival (PFS) compared to the combination of bevacizumab and paclitaxel…more
Plus – encouraging Gardasil results in older women; and encouraging melanoma results (finally!) with a new experimental drug (from Roche/Plexxikon)
——
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Leave a Reply